¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"blood group antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • blood cell separator
    Ç÷±¸ºÐ¸®±â
  • blood clot
    Çǵ¢ÀÌ, ÇǶ±
  • blood clotting
    Ç÷¾×ÀÀ°í
  • blood coagulation
    Ç÷¾×ÀÀ°í
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • blood concentration
    Ç÷Áß³óµµ
  • blood count
    Ç÷±¸°è»ê
  • blood crust
    ÇǵüÁö
  • blood depot reservoir
    Ç÷¾×ÀúÀå¼Ò
  • blood derivative
    Ç÷¾×À¯µµÃ¼
  • blood disk
    Ç÷¼ÒÆÇ
  • blood donation
    ÇåÇ÷
  • blood donor
    ÇåÇ÷ÀÚ, °øÇ÷ÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • somatic antigen
    ü¼¼Æ÷Ç׿ø, ±ÕüÇ׿ø
  • specific antigen
    ƯÀÌÇ׿ø
  • surface antigen
    Ç¥¸éÇ׿ø
  • thymus-dependent antigen
    °¡½¿»ùÀÇÁ¸Ç׿ø
  • thymus-independent antigen
    °¡½¿»ùºñÀÇÁ¸Ç׿ø
  • transplantation antigen
    À̽ÄÇ׿ø
  • tumor antigen
    Á¾¾çÇ׿ø
  • type specific antigen
    ÇüƯÀÌÇ׿ø
  • human leukocyte antigen complex
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕü
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
  • T cell antigen receptor
    Ƽ¼¼Æ÷Ç׿ø¼ö¿ëü
  • allowable blood loss
    Çã¿ë½ÇÇ÷·®
  • arterial blood
    µ¿¸ÆÇ÷¾×, µ¿¸ÆÇÇ
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • artificial blood
    ÀΰøÇ÷¾×
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • CA 50 antigen
    CA 50 Ç׿ø
  • CA-2<>
    CA-2<<ÄÝ·ÎÀ̵åÇ׿ø>>
  • CD5 antigen
    CD5 Ç׿ø
  • CEA(carcinoembryonic antigen)
    žƼº¾ÏÇ׿ø
  • Cartwright antigen
    īƮ¶óÀÌÆ®Ç׿ø
  • Cha antigen
    Cha Ç׿ø
  • Chido (Ch") antigen
    Chido(Ch") Ç׿ø
  • D antigen
    D Ç׿ø
  • D antigen
    DÇ׿ø
  • D-related antigen
    D-°ü·ÃÇ׿ø
  • DP antigen
    DPÇ׿ø
  • DQ antigen
    DQÇ׿ø
  • DR antigen
    DRÇ׿ø
  • Diego antigen
    µð¿¡°íÇ׿ø
  • EB nuclear antigen(EBNA0
    EB ¹ÙÀÌ·¯½º ÇÙÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • antigen detection
    Ç׿ø°ËÃâ
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö(ù÷ê«üªß¤ßÈâ¦).
  • antigen drift
    Ç׿ø¼Òº¯ÀÌ.
  • antigen excess
    Ç׿ø°ú´Ù(ù÷ê«Î¦Òý).
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen mimicry
    Ç׿øÀ¯»ç¼º.
  • antigen modification
    Ç׿øº¯Çü.
  • antigen presentation
    Ç׿øÁ¦°ø, Ç׿øÀü´Þ, Ç׿øÁ¦½Ã
  • antigen presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷.
  • antigen presenting cells
    Ç׿ø Àü´Þ ¼¼Æ÷
  • antigen reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷.
  • antigen receptor
    Ç׿ø¼ö¿ëü.
  • antigen recognition
    Ç׿øÀÎÁö
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • phosphatidyl group
    Æ÷½ºÆÄƼµô±â(Ðñ)
  • phosphoryl group
    ÀλêÈ­±â(×òß«ûùÐñ)
  • phosphoryl-group carrier
    ÀλêÈ­±â ¿î¹Ýü(×òß«ûùÐñê¡Úæô÷)
  • phosphoryl-group transfer
    ÀλêÈ­±â ÀüÀÌ(×òß«ûùÐñï®ì¹)
  • prenyl group
    ÇÁ·¹´Ò±â(Ðñ)
  • prosthetic group
    º¸Á¶ ºÐÀÚÁ·(ÜÍð¾ÝÂí­ðé)
  • protecting group
    º¸È£Á·(ÜÁûÞðé)
  • prototropic group
    ¾ç¼ºÀÚ¼º ±â(åÕàõí­àõÐñ)
  • reporter group
    Áö½Ã±â(ò¦ãÆÐñ)
  • R group
    R ±â(Ðñ)
  • SH-group
    SH-±â(Ðñ)
  • sialosyl group
    »çÀ̾˷νDZâ(Ðñ)
  • sialoyl group
    »çÀ̾˷ÎÀϱâ(Ðñ)
  • sulfhydryl group
    ¼³ÇÁÇÏÀ̵帱±â(Ðñ)
  • t-Boc group
    t-Boc ±â (Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
LA lactic acid; large amount; laser angioplasty; late abortion; late antigen; latex agglutination; left...
LFA left femoral artery; left frontal craniotomy; left fronto-anterior [fetal position]; leukocyte funct...
MSA major serologic antigen; male-specific antigen; mannitol salt agar; Medical Services Administration;...
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
SSAA sicca syndrome associated antigen A; Sjogren syndrome-associated antigen A; syringomyelia secondary ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
G3 Group 3
GAS Group A Streptococcal
GAS Group A Streptococci
GAS Group A Streptococcus
GABHS Group A beta haemolytic streptococcus
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • blood transfusion
    ¼öÇ÷
    Ç÷¾×¿¡ Ç×ÀÀ°íÁ¦¸¦ ÷°¡ÇÑ °ÍÀ» Á¤¸Æ³»¿¡ ÁÖ»çÇÏ´Â °ÍÀ» ¸»Çϸç, º¸Åë ´Ù¸¥ »ç¶÷À¸·ÎºÎÅÍ Ã¤Ç÷ÇÑ °ÍÀ» ¼öÇ÷ÇÑ´Ù.
  • blood type
    Ç÷¾×Çü
  • blood typing
    Ç÷¾×Çü ÆÇÁ¤
  • blood vessel
    Ç÷°ü, ÇÍÁÙ
    Ç÷¾×À» ½ÉÀåÀ¸·ÎºÎÅÍ Á¶Á÷À» °ÅÃÄ ½ÉÀåÀ¸·Î µÇµ¹¾Æ¿À°Ô ÇÏ´Â ¼øÈ¯°è.
  • blood vessel swimming
    ?
  • blood volume
    Ç÷¾×·®, Ç÷¾× ¼øÈ¯·®
  • blood-brain barrier
    Ç÷³ú À庮
    ³ú¿Í ô¼ö¿¡´Â Ç÷·ù·ÎºÎÅÍ ¾î¶² ¹°ÁúÀÌ À¯ÀԵǴ °ÍÀ» ¸·´Â À庮ÀÌ Á¸ÀçÇϰí À̰ÍÀ» Ç÷³ú À庮À̶ó ÇÑ´Ù. À̰ÍÀº ³ú¿Í ô¼ö¿¡ Á¸ÀçÇÏ´Â ¸ð¼¼Ç÷°üÀÇ Åõ°ú¼ºÀÌ ´Ù¸¥ ¸ð¼¼Ç÷°ü¿¡ ºñÇØ ¶³¾îÁö±â ¶§¹®ÀÌ´Ù.
  • blood-bronchial barrier
    Ç÷¾×-±â°üÁö À庮
  • blood-tinged
    Ç÷¾×ÀÌ ¾à°£ ¼¯ÀÎ
  • bone-marrow blood transfusion
    °ñ¼ö ¼öÇ÷
    °æ°ñ°ú Èä°ñÀÇ °ñ¼ö¿¡ Ç÷¾×À» ÁÖÀÔÇÏ´Â ¼öÇ÷ÀÇ º¯¹ý. Ç×»ó ¾²´Â Á¤¸Æ ³» ¼öÇ÷·Î´Â °¨¼ö¼ºÀÌ Áö³ªÄ¡°Ô °­Çϰųª ¸öÀÌ ºñ¸¸ÇÏ¿© Á¤¸ÆÀ» ã±â ¾î·Á¿î ȯÀÚ ¶Ç´Â À¯¾Æ¸¦ ´ë»óÀ¸·Î ÇÒ °æ¿ì ÀÌ ¹æ¹ýÀ¸·Î ¼öÇ÷ÇÒ ¶§°¡ ÀÖ´Ù. ¶Ç ¹éÇ÷º´À̳ª Àç»ýºÒ·®¼º ºóÇ÷ ȯÀÚ¿¡°Ô´Â ÀÌ ¹æ¹ýÀÌ Á¤¸Æ ¼öÇ÷º¸´Ù ¶Ù¾î³­ È¿°ú°¡ ÀÖ´Ù´Â °ßÇØµµ ÀÖ´Ù. ¹æ¹ýÀº °ñ¼ö õÀÚ¸¦ ÇÏ¿© Á¡Àû ÀåÄ¡ ¶Ç´Â ´ëÇü ÁÖ»ç±â·Î äÇ÷ÇÑ Ç÷¾×À» °ñ¼ö ³»¿¡ ÁÖÀÔÇÑ´Ù. ´Ù·® ¼öÇ÷ÀÌ °¡´ÉÇÏÁö¸¸, ±¹ºÎ ÇÇºÎ¿Í °ñ¸·¿¡ ±¹¼Ò¸¶Ã븦 ÇØ¾ß ÇÒ Çʿ䰡 ÀÖ´Ù. ±×¸®°í Á¤¸Æ ¼öÇ÷º¸´Ù ½Ã°£ÀÌ °É¸®°í ¼¼½ÉÇÑ ÁÖÀǰ¡ ÇÊ¿äÇϸç, ȯÀÚ¿¡°Ô °íÅëÀ» Áְųª, ³Ê¹« »¡¸® ÁÖÀÔÇÏ¸é ±¹¼Ò¿¡ ÅëÁõÀ» ÁÖ´Â µîÀÇ °áÁ¡ÀÌ ÀÖ´Ù.
  • circulating blood volume
    ¼øÈ¯ Ç÷¾×·®
  • collection of blood sample
    äÇ÷
  • complete blood count
    ÀüÇ÷ °Ë»ç, ÀüÇ÷±¸ °è»ê
  • continuous flow blood analysis
    Áö¼Ó¼º À¯µ¿ Ç÷¾× ºÐ¼®
  • coronary blood flow
    °üÇ÷·ù, °ü»ó Ç÷·ù
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
functional group 1. <chemistry> The specific atom that give a biomolecule a specific chemical characteristic.
2. <ecology> This ecological term refers to groups of organisms that obtain energy in similar ways. Autotrophic plants fix energy from sunlight. Fungi and bacteria decompose organic matter. Shredders chew large particles like tree leaves. Scrapers rasp periphyton and microbes from solid surfaces. Collectors filter fine particles from the water or gather them from deposits.
(05 Jan 1998)
linkage group A set of two or more loci that have been shown by linkage analysis to be physically close in the genome but that have not yet been assigned to specific chromosomes. It is rapidly becoming an outmoded term.
(05 Mar 2000)
llandeilo group <geology> A series of strata in the lower Silurian formations of Great Britain; so named from Llandeilo in Southern Wales. See Chart of Geology.
Source: Websters Dictionary
(01 Mar 1998)
ludlow group <geology> A subdivision of the British Upper Silurian lying below the Old Red Sandstone; so named from the Ludlow, in Western England.
Source: Websters Dictionary
(01 Mar 1998)
acetone-insoluble antigen A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis.
(18 Nov 1997)
allogeneic antigen Genetic variations of the same antigens within a given species.
(05 Mar 2000)
antigen Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun.
See: early gene.
(18 Nov 1997)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antigen-combining site See: paratope.
(05 Mar 2000)
antigen excess In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases.
(05 Mar 2000)
antigen interferon <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
antigen p150,95 A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions.
(12 Dec 1998)
antigen presentation A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin.
See: MHC restriction, histocompatibility antigens.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
ÅëÇÕ°Ë»ö ¿Ï·á